metformin has been researched along with Colorectal Cancer in 165 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy." | 9.27 | Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018) |
| "Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases." | 9.27 | The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. ( Bachleitner-Hofmann, T; Briata, IM; Caviglia, S; Clavarezza, M; DeCensi, A; Gnant, M; Haefeli, WE; Mislej, EM; Oppezzi, M; Paleari, L; Petrera, M; Puntoni, M; Roth, W; Scherer, D; Stabuc, B; Ulrich, CM, 2018) |
| "Whether metformin is a protective factor of colorectal cancer (CRC) among CRC patients is still not entirely clear." | 9.22 | Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis. ( Shi, M; Wang, Q, 2022) |
| "Observational and preclinical studies have suggested that metformin has antitumor effects in solid tumors, including colorectal cancer (CRC)." | 9.22 | Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. ( Alex, A; Bariani, G; Bezerra Neto, JE; Braghiroli, MI; Capareli, FC; Faria, LD; Hoff, PM; Lobo Dos Santos, JF; Miranda, VC; Riechelmann, RP; Sabbaga, J, 2016) |
| "In this review, current data was used to elucidate the mechanisms by which metformin hydrochloride exerts chemopreventive effects on colorectal cancer (CRC)." | 9.12 | Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer. ( Jaromy, M; Miller, JD, 2021) |
| " Metformin use was negatively associated with the incidence of colorectal adenoma (RR: 0." | 9.05 | Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. ( Deng, M; Huang, D; Lei, S; Wang, H; Wu, Y; Xia, S; Xu, E; Zhang, H, 2020) |
| "To evaluate the effect of metformin as a treatment for the mortality of colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM)." | 9.05 | Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences. ( Du, J; Du, S; Wang, Y; Xiao, J; Zhao, Y, 2020) |
| "Metformin may have a role in reducing the incidence of colorectal cancer (CRC) and improving survival outcome." | 9.05 | Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. ( Chong, CS; Jiang, AA; Khoo, CM; Ng, CH; Ng, CW; Ong, ZH; Peng, S; Sundar, R; Tham, HY; Toh, EMS, 2020) |
| "At present, there are many studies on metformin and the risk of colorectal cancer in patients with diabetes, but the conclusions are contradictory." | 9.05 | Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis. ( Liu, JL; Yang, HJ; Yang, WT; Zhou, JG, 2020) |
| "Metformin using was associated with an increased OS rate and CS rate of colorectal cancer." | 9.05 | For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis. ( Chen, Y; Cheng, Y; Liu, C; Shen, L; Tu, F; Xu, J; Zhou, C, 2020) |
| "Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma." | 8.95 | Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis. ( Eun, CS; Han, DS; Jung, YS; Park, CH; Park, DI, 2017) |
| "Existing data evaluating the impact of metformin on the colorectal adenoma (CRA) risk in patients suffering from type 2 diabetes (T2D) are limited and controversial." | 8.95 | Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis. ( Fang, JY; Hou, YC; Hu, Q; Huang, J; Xiong, H, 2017) |
| "Recent evidence indicates that metformin therapy may be associated with a decreased colorectal adenoma/colorectal cancer risk in type 2 diabetes patients." | 8.95 | Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. ( Chu, Y; Li, X; Liu, F; Liu, Y; Lu, Y; Nie, S; Rui, D; Wang, Z; Xiang, H; Yan, L, 2017) |
| "Several observational studies have shown that metformin can modify the risk and survival of colorectal cancer (CRC) in patients with diabetes mellitus, although the magnitude of this relationship has not been determined." | 8.95 | Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies. ( Bi, C; Cheng, Z; Du, L; Guo, M; Kang, Y; Li, B; Wang, M, 2017) |
| "To systematically assess the effect of metformin on colorectal cancer (CRC) risk and mortality in type 2 diabetes mellitus (T2DM) patients." | 8.93 | Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. ( He, XK; Si, JM; Su, TT; Sun, LM, 2016) |
| "We searched EMBASE and MEDLINE databases from inception through August, 2013, using search terms related to metformin, diabetes, colorectal cancer, and prognostic outcome." | 8.90 | Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. ( Cui, A; Cui, L; Liang, ZL; Liu, CY; Liu, Y; Mei, ZB; Wang, GH; Zhang, ZJ, 2014) |
| "The PubMed and SciVerse Scopus databases were searched to identify studies that examined the effect of metformin therapy on colorectal cancer among patients with type 2 diabetes." | 8.87 | Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. ( Cui, W; Kan, H; Kip, KE; Song, Y; Zhang, ZJ; Zhao, G; Zheng, ZJ, 2011) |
| "To investigate the impact of metformin on survival of diabetic patients following surgery for colorectal cancer (CRC)." | 8.31 | The impact of metformin on survival in diabetes patients with operable colorectal cancer: A nationwide retrospective cohort study. ( Chu, PT; Chuang, TJ; Huang, SH; Huang, WC; Wang, JH; Wu, TH, 2023) |
| " Metformin has been reported to play a role in stimulating antitumor immunity, suggesting it could be used to overcome immunosuppression in colorectal cancer." | 8.31 | Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer. ( Chen, H; Du, W; Hong, X; Huang, X; Su, W; Sun, D; Sun, T; Wang, J; Xiong, H; Yan, T; Yang, C; Yu, T; Zhou, C, 2023) |
| "To investigate the mechanism of metformin for inhibiting self-renewal of colorectal cancer stem cells (CSCs)." | 8.31 | [Metformin inhibits self-renewal of colorectal cancer stem cells by inhibiting mitochondrial oxidative phosphorylation]. ( Hu, Y; Liu, S; Song, Q; Yan, C, 2023) |
| "This present study aims to explore the influence of metformin and postoperative insulin pump use on colorectal cancer (CRC) patients with type II diabetes mellitus (T2DM) who received surgery in terms of short-term and long-term outcomes." | 8.31 | The Use of Metformin and Postoperative Insulin Pump Were Predictive Factors for Outcomes of Diabetic Colorectal Cancer Patients after Surgery. ( Li, LS; Li, ZW; Liu, F; Liu, XR; Lv, Q; Peng, D; Shu, XP; Tong, Y; Zhang, W, 2023) |
| " Metformin may decrease the overall incidence of cancer in patients with diabetes and may decrease the incidence of colorectal cancer." | 8.12 | Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas. ( Abrams, JA; Araujo, JL; Buitrago, C; Huang, CH; Karkenny, G; Krigel, A; Lebwohl, B; Nguyen, STT; Talukder, N, 2022) |
| "Metformin inhibits oxidative phosphorylation and can be used to dissect metabolic pathways in colorectal cancer (CRC) cells." | 8.12 | A functional screen with metformin identifies microRNAs that regulate metabolism in colorectal cancer cells. ( Ali, SR; Aloia, AL; McKinnon, RA; Michael, MZ; Orang, A; Petersen, J, 2022) |
| "Multiple evidence shows that metformin serves as a potential agent for Colorectal Cancer (CRC) treatment, while its molecular mechanisms still require detailed investigation." | 8.12 | Metformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-β/PI3K/AKT signaling transduction. ( Liu, J; Shu, G; Xiao, J; Xiao, Q; Yin, G, 2022) |
| "Evidence from previous studies suggests a protective effect of metformin in patients with colorectal cancer (CRC)." | 8.12 | The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus. ( Christou, N; Jost, J; Magne, J; Manceur, K; Mathonnet, M; Tarhini, Z, 2022) |
| "This study aimed to investigate the association between metformin usage and the risk of colorectal cancer (CRC) using data from the Korean National Health Insurance Service-National Health Screening Cohort database." | 8.02 | Metformin usage and the risk of colorectal cancer: a national cohort study. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, JW; You, HS, 2021) |
| "We aimed to estimate colorectal cancer risk in patients with type 2 diabetes mellitus (T2DM) using metformin." | 7.96 | Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: national cohort study. ( Dulskas, A; Linkeviciute-Ulinskiene, D; Patasius, A; Smailyte, G; Urbonas, V; Zabuliene, L, 2020) |
| "Epidemiological evidence for the association between postdiagnostic metformin use and survival in patients with colorectal cancer (CRC) remains limited." | 7.96 | Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study. ( Chang, JW; Chang, SH; Chen, JS; Chou, WC; Hsu, HC; Huang, WK; Kuo, CF; Lin, YC; See, LC; Yang, TS, 2020) |
| "Metformin use prior to diagnosis of cancer was associated with a decrease in risk of both breast cancer (OR = 0." | 7.96 | Use of metformin and risk of breast and colorectal cancer. ( Gronich, N; Gruber, SB; Pinchev, M; Rennert, G; Rennert, HS, 2020) |
| "Accumulating evidence suggests that metformin reduces the incidence and mortality of colorectal cancer (CRC)." | 7.96 | Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. ( Horie, H; Kawahira, H; Kitayama, J; Koinuma, K; Lefor, AK; Mimura, T; Ohzawa, H; Saito, A; Sata, N; Yamaguchi, H, 2020) |
| "The purpose of this study was to investigate the effect of metformin or the combination of metformin and 5-FU on the growth and metastasis of colorectal cancer (CRC)." | 7.96 | Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU. ( Sang, J; Sun, Q; Tang, R; Yang, M, 2020) |
| "Metformin may be associated with reduced colorectal cancer (CRC) risk, but findings from previous studies have been inconsistent and had insufficient sample sizes to examine whether the association differs by anatomic site." | 7.91 | Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes. ( Bustamante, R; Demb, J; Earles, A; Gawron, AJ; Ghosh, P; Gupta, S; Gutkind, JS; Kaltenbach, TR; Liu, L; Martinez, ME; Yaseyyedi, A, 2019) |
| "The present study aimed to examine the roles and mechanisms of metformin in the stemness and epithelial‑mesenchymal transition (EMT) of colorectal cancer cells." | 7.91 | Metformin attenuates cells stemness and epithelial‑mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β‑catenin pathway. ( Wang, Y; Zhang, C, 2019) |
| " In this study, we describe the inhibitory effect of metformin in interleukin 8 (IL-8) upregulation by lithocholic acid (LCA) in HCT116 colorectal cancer (CRC) cells." | 7.91 | Metformin inhibits lithocholic acid-induced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity. ( Do Jung, Y; Li, S; Lian, S; Nguyen, TT; Park, SY; Ung, TT; Xia, Y, 2019) |
| " Here, we proposed to assess the anti-EMT abilities and explore the inherent pharmacological mechanisms of the classic hypoglycaemic agent metformin for colorectal cancer(CRC)." | 7.88 | The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC). ( Hu, L; Wang, Y; Wu, Z, 2018) |
| "Purpose Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients with colorectal cancer (CRC) and type II diabetes mellitus (DM)." | 7.88 | Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer. ( Abdelkhaleq, H; Al Omari, A; Al-Hussaini, M; Alfaqih, MA; Awad, N; Garrett, CR; Hassan, MM; Turfa, R, 2018) |
| "The antidiabetic drug metformin has been associated with reduced colorectal cancer (CRC) risk and improved prognosis of CRC patients." | 7.88 | Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling. ( Calin, GA; Chen, M; Knutsen, E; Ling, H; Pichler, M; Reineke, LC; Shen, P, 2018) |
| "The association between metformin and colorectal cancer (CRC) has rarely been investigated in Asian populations." | 7.85 | Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis. ( Tseng, CH, 2017) |
| "To assess factors associated with the higher effect of metformin on mortality in diabetic colorectal cancer (CRC) patients, since the factors related to the effectiveness of metformin have not been identified yet." | 7.85 | Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. ( Cheon, JH; Kim, TI; Kim, WH; Lee, JH; Park, JW; Park, SJ; Park, YH, 2017) |
| "The function of metformin in colorectal cancer (CRC) patients with diabetes mellitus (DM) remains a controversial topic because studies are increasingly focusing on epidemiologic features." | 7.85 | Metformin depresses overactivated Notch1/Hes1 signaling in colorectal cancer patients with type 2 diabetes mellitus. ( Chen, S; Han, FH; Huang, CZ; Liu, GJ; Liu, Q; Yang, B; Yu, T; Zhou, SN, 2017) |
| "Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer." | 7.85 | The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. ( Cheon, JH; Han, MS; Hong, SP; Kim, TI; Kim, WH; Lee, HJ; Park, SJ, 2017) |
| "Emerging evidence suggests that metformin decreases the risk of developing colorectal cancer in patients with diabetes, but only few studies have examined potential survival benefits after surgery for colorectal cancer (CRC)." | 7.83 | Metformin Increases Overall Survival in Patients with Diabetes Undergoing Surgery for Colorectal Cancer. ( Fransgaard, T; Gögenur, I; Thygesen, LC, 2016) |
| "Metformin has been associated with improved colorectal cancer survival, but investigations are limited by small numbers of patients and confounding by diabetic severity." | 7.83 | Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. ( Cossor, FI; Kelley, MJ; Martell, RE; Paulus, JK; Williams, CD, 2016) |
| "Emerging evidence from observational studies has suggested that metformin may be beneficial in the primary prevention of colorectal cancer (CRC)." | 7.81 | Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. ( Bissonnette, MB; Olopade, OI; Polite, BN; Sehdev, A; Shih, YC; Vekhter, B, 2015) |
| "To investigate the effect of metformin on silibinin-induced apoptosis in human colorectal cancer (COLO 205) cells." | 7.81 | Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells. ( Chen, LJ; Cheng, JT; Chuang, TW; Chung, KM; Lin, KC; Niu, HS; Tsai, CC, 2015) |
| "Existing literature suggests that metformin, the most commonly used biguanide, may lower colorectal cancer risk." | 7.81 | Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. ( Corley, DA; Doubeni, CA; Jensen, CD; Marks, AR; Pietrofesa, RA; Zebrowski, A, 2015) |
| "The present study addressed whether the combination of metformin and ionizing radiation (IR) would show enhanced antitumor effects in radioresistant p53-deficient colorectal cancer cells, focusing on repair pathways for IR-induced DNA damage." | 7.81 | Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins. ( Ha, H; Jeong, YK; Kim, EH; Kim, MS; Lee, JY, 2015) |
| "While overall there was no statistically significant association between metformin exposure and disseminated colorectal cancer at diagnosis, there was a suggestion that high intensity, exclusive metformin use may be associated with reduced odds of disseminated disease." | 7.80 | Metformin exposure and disseminated disease in patients with colorectal cancer. ( Barron, TI; Bennett, K; Sharp, L; Spillane, S, 2014) |
| "In vitro and animal studies indicate that metformin prevents colorectal cancer (CRC)." | 7.80 | Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. ( Cardel, M; Hallas, J; Jensen, SM; Jørgensen, TL; Pottegård, A, 2014) |
| "Preclinical evidence suggests a beneficial effect of metformin in colorectal cancer." | 7.79 | A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. ( Barron, TI; Bennett, K; Sharp, L; Spillane, S, 2013) |
| "Observational studies have associated metformin use with lower colorectal cancer (CRC) incidence but few studies have examined metformin's influence on CRC survival." | 7.79 | Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. ( Adams-Campbell, LL; Chlebowski, RT; Cossor, FI; Gunter, MJ; Johnson, K; Martell, RE; McTiernan, A; Paulus, JK; Rohan, T; Simon, MS; Wallace, RB, 2013) |
| "Experimental studies have suggested that metformin may decrease the incidence of colorectal cancer in patients with type II diabetes." | 7.79 | The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. ( Azoulay, L; Pollak, MN; Smiechowski, B; Suissa, S; Yin, H, 2013) |
| "In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality." | 7.79 | Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013) |
| "To explore the association between use of metformin or other antidiabetic drugs and the risk of colorectal cancer." | 7.78 | Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. ( Becker, C; Bodmer, M; Jick, SS; Meier, C; Meier, CR, 2012) |
| "Colorectal cancer patients with DM treated with metformin as part of their diabetic therapy appear to have a superior OS." | 7.78 | Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. ( Baladandayuthapani, V; Bhadkamkar, NA; Eng, C; Garrett, CR; Hassabo, HM; Hassan, MM; Kee, BK; Wen, S, 2012) |
| "This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer." | 7.78 | Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "Inflammation is one biological mechanism hypothesized to mediate these associations." | 6.94 | Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. ( Abrams, TA; Brown, JC; Campbell, N; Cartmel, B; Douglas, PS; Fuchs, CS; Harrigan, M; Hu, FB; Irwin, ML; Jones, LW; Ligibel, JA; Meyerhardt, JA; Ng, K; Pollak, MN; Sanft, T; Sorrentino, A; Tolaney, SM; Winer, EP; Zhang, S, 2020) |
| "The incidence and mortality rates of colorectal cancer (CRC) continue to increase worldwide." | 6.94 | The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial. ( Arimoto, J; Ashikari, K; Fuyuki, A; Higurashi, T; Matsuura, T; Misawa, N; Nakajima, A; Ohkubo, H; Takatsu, T; Yoshihara, T, 2020) |
| "GDF-15 was not associated with type 2 diabetes, glycaemic traits, CAD risk factors or colorectal cancer." | 6.90 | The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. ( Au Yeung, SL; Luo, S; Schooling, CM, 2019) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 6.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "Metformin, a biguanide, has been widely used in treating diabetes." | 6.61 | Metformin: A Salutary Candidate for Colorectal Cancer Treatment in Patients with Diabetes. ( Chellappan, DK; Dahiya, R; Dua, K; Gubbiyappa, SK; Gupta, G; Sah, SK; Samuel, VP; Singh, Y, 2019) |
| "Studies on patients with type 2 diabetes treated with metformin analyzed data on total of 146 496 patients." | 6.61 | Metformin and Colorectal Cancer - A Systematic Review. ( Dobrzycka, M; Jędrusik, P; Kobiela, J; Kobiela, P; Śledziński, Z; Spychalski, P; Zdrojewski, T, 2019) |
| "Diabetic patients have a higher risk of colorectal cancer (CRC)." | 6.53 | Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. ( Gu, M; Nie, Z; Zhu, H, 2016) |
| "Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes." | 5.72 | The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022) |
| "But its role in the development of colorectal cancer (CRC) cancer remains unknown." | 5.72 | FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. ( Deng, H; He, Z; Li, G; Mou, T; Shi, J; Sui, C; Sun, K; Wang, T; Wang, Y; Xu, Z; Yang, J; Zhang, P; Zhuang, B, 2022) |
| "The association between type 2 diabetes mellitus (DM) and colorectal cancer (CRC) has been thoroughly investigated and reports have demonstrated that the risk of CRC is increased in DM patients." | 5.72 | Effects of diabetes type 2 and metformin treatment in Swedish patients with colorectal cancer. ( Dimberg, J; Landerholm, K; Shamoun, L; Wågsäter, D, 2022) |
| "Metformin is a commonly used drug for the treatment of diabetes." | 5.72 | Metformin inhibits the development and metastasis of colorectal cancer. ( Hasegawa, H; Ishida, T; Kitagawa, Y; Okabayashi, K; Seishima, R; Shigeta, K; Sugiura, K; Tsuruta, M, 2022) |
| "Metformin (MT) was recently approved as anticancer drug against solid tumors, such as CRC." | 5.62 | Metformin-loaded lecithin nanoparticles induce colorectal cancer cytotoxicity via epigenetic modulation of noncoding RNAs. ( Abd-Rabou, AA; Abdelaziz, AM; Ayeldeen, G; Shaker, OG, 2021) |
| "We used two colorectal cancer cell lines with different growth rates and clinically achievable metformin concentrations." | 5.62 | Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells. ( Alhourani, AH; Bokil, AA; Hagland, HR; Røsland, GV; Søreide, K; Tidwell, TR; Tronstad, KJ, 2021) |
| "Metformin and cisplatin have been widely studied as antitumor agents." | 5.56 | Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway. ( Liu, H; Lu, X; Shi, Z; Zhang, P; Zhao, S; Zhu, B, 2020) |
| "Metformin has been known to suppress cancer stem cells (CSCs) in some cancers." | 5.48 | Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. ( Cheon, JH; Hong, SP; Il Kim, T; Kang, JY; Kim, JH; Kim, WH; Kwon, JH; Lee, HJ; Lee, KJ; Park, SJ; Seo, Y; Yoon, JP, 2018) |
| "Metformin treatment has been associated with a reduced risk of developing cancer, but whether metformin influences the risk of recurrence is unknown." | 5.48 | Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study. ( Fransgaard, T; Gögenur, I; Thygesen, LC, 2018) |
| "With no sharp cure, breast cancer still be the major and the most serious life-threatening disease worldwide." | 5.48 | Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells ( Abdel-Ghany, SE; El-Zawahry, M; M Said, OA; Mostafa, MA; Sabit, H, 2018) |
| "The CRC colorectal cancer (CRC) cell lines HCT116 wild-type (wt), HCT116 p53-/-, and HT-29 (mutant; R273H) were employed, covering three different p53 variations." | 5.46 | Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells. ( Abu El Maaty, MA; Dabiri, Y; Qaiser, T; Strassburger, W; Wölfl, S, 2017) |
| "Metformin is a widely used and well-tolerated anti-diabetic drug that can reduce cancer risk and improve the prognosis of certain malignancies." | 5.46 | Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. ( Belfiore, A; Bozzi, F; Gariboldi, M; Gloghini, A; Maiorana, MV; Mogavero, A; Pierotti, MA; Varinelli, L; Volpi, CC; Zanutto, S, 2017) |
| "Metformin use was identified from CPRD prescription records." | 5.43 | Metformin use and survival after colorectal cancer: A population-based cohort study. ( Cardwell, CR; Hughes, CM; Mc Menamin, ÚC; Murray, LJ, 2016) |
| "Metformin is an anti-diabetic drug with a promising anti-cancer potential." | 5.43 | Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. ( Jeong, YA; Jo, MJ; Kim, BR; Kim, JL; Lee, DH; Lee, SI; Lee, SY; Lee, YY; Na, YJ; Oh, SC; Park, SH, 2016) |
| "Metformin use was associated with decreased overall mortality (p = 0." | 5.38 | The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "Metformin is known to lower the risk of cancer and cancer mortality." | 5.38 | [The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes]. ( Cheon, JH; Hong, SP; Kim, B; Kim, TI; Kim, WH; Lee, DJ; Lee, JH; Park, SJ, 2012) |
| "Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy." | 5.27 | Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018) |
| "Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases." | 5.27 | The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. ( Bachleitner-Hofmann, T; Briata, IM; Caviglia, S; Clavarezza, M; DeCensi, A; Gnant, M; Haefeli, WE; Mislej, EM; Oppezzi, M; Paleari, L; Petrera, M; Puntoni, M; Roth, W; Scherer, D; Stabuc, B; Ulrich, CM, 2018) |
| "Whether metformin is a protective factor of colorectal cancer (CRC) among CRC patients is still not entirely clear." | 5.22 | Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis. ( Shi, M; Wang, Q, 2022) |
| "Observational and preclinical studies have suggested that metformin has antitumor effects in solid tumors, including colorectal cancer (CRC)." | 5.22 | Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. ( Alex, A; Bariani, G; Bezerra Neto, JE; Braghiroli, MI; Capareli, FC; Faria, LD; Hoff, PM; Lobo Dos Santos, JF; Miranda, VC; Riechelmann, RP; Sabbaga, J, 2016) |
| "In this review, current data was used to elucidate the mechanisms by which metformin hydrochloride exerts chemopreventive effects on colorectal cancer (CRC)." | 5.12 | Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer. ( Jaromy, M; Miller, JD, 2021) |
| " Metformin use was negatively associated with the incidence of colorectal adenoma (RR: 0." | 5.05 | Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. ( Deng, M; Huang, D; Lei, S; Wang, H; Wu, Y; Xia, S; Xu, E; Zhang, H, 2020) |
| "To evaluate the effect of metformin as a treatment for the mortality of colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM)." | 5.05 | Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences. ( Du, J; Du, S; Wang, Y; Xiao, J; Zhao, Y, 2020) |
| "Metformin may have a role in reducing the incidence of colorectal cancer (CRC) and improving survival outcome." | 5.05 | Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. ( Chong, CS; Jiang, AA; Khoo, CM; Ng, CH; Ng, CW; Ong, ZH; Peng, S; Sundar, R; Tham, HY; Toh, EMS, 2020) |
| "At present, there are many studies on metformin and the risk of colorectal cancer in patients with diabetes, but the conclusions are contradictory." | 5.05 | Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis. ( Liu, JL; Yang, HJ; Yang, WT; Zhou, JG, 2020) |
| "Metformin using was associated with an increased OS rate and CS rate of colorectal cancer." | 5.05 | For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis. ( Chen, Y; Cheng, Y; Liu, C; Shen, L; Tu, F; Xu, J; Zhou, C, 2020) |
| "Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma." | 4.95 | Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis. ( Eun, CS; Han, DS; Jung, YS; Park, CH; Park, DI, 2017) |
| "To evaluate the colorectal cancer (CRC) prevention effect of metformin in comparison with that of other T2DM medications from a Markov model perspective." | 4.95 | [Effect of metformin on colorectal carcinoma in type 2 diabetes mellitus patients: a Markov model analysis]. ( Dong, Y; Li, B; Liao, B; Peng, S; Peng, Z; Su, T; Zhang, N; Zhou, Q, 2017) |
| "Existing data evaluating the impact of metformin on the colorectal adenoma (CRA) risk in patients suffering from type 2 diabetes (T2D) are limited and controversial." | 4.95 | Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis. ( Fang, JY; Hou, YC; Hu, Q; Huang, J; Xiong, H, 2017) |
| "Recent evidence indicates that metformin therapy may be associated with a decreased colorectal adenoma/colorectal cancer risk in type 2 diabetes patients." | 4.95 | Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. ( Chu, Y; Li, X; Liu, F; Liu, Y; Lu, Y; Nie, S; Rui, D; Wang, Z; Xiang, H; Yan, L, 2017) |
| "Several observational studies have shown that metformin can modify the risk and survival of colorectal cancer (CRC) in patients with diabetes mellitus, although the magnitude of this relationship has not been determined." | 4.95 | Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies. ( Bi, C; Cheng, Z; Du, L; Guo, M; Kang, Y; Li, B; Wang, M, 2017) |
| "To systematically assess the effect of metformin on colorectal cancer (CRC) risk and mortality in type 2 diabetes mellitus (T2DM) patients." | 4.93 | Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. ( He, XK; Si, JM; Su, TT; Sun, LM, 2016) |
| "We searched EMBASE and MEDLINE databases from inception through August, 2013, using search terms related to metformin, diabetes, colorectal cancer, and prognostic outcome." | 4.90 | Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. ( Cui, A; Cui, L; Liang, ZL; Liu, CY; Liu, Y; Mei, ZB; Wang, GH; Zhang, ZJ, 2014) |
| "The PubMed and SciVerse Scopus databases were searched to identify studies that examined the effect of metformin therapy on colorectal cancer among patients with type 2 diabetes." | 4.87 | Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. ( Cui, W; Kan, H; Kip, KE; Song, Y; Zhang, ZJ; Zhao, G; Zheng, ZJ, 2011) |
| "To investigate the impact of metformin on survival of diabetic patients following surgery for colorectal cancer (CRC)." | 4.31 | The impact of metformin on survival in diabetes patients with operable colorectal cancer: A nationwide retrospective cohort study. ( Chu, PT; Chuang, TJ; Huang, SH; Huang, WC; Wang, JH; Wu, TH, 2023) |
| " Metformin has been reported to play a role in stimulating antitumor immunity, suggesting it could be used to overcome immunosuppression in colorectal cancer." | 4.31 | Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer. ( Chen, H; Du, W; Hong, X; Huang, X; Su, W; Sun, D; Sun, T; Wang, J; Xiong, H; Yan, T; Yang, C; Yu, T; Zhou, C, 2023) |
| "To investigate the mechanism of metformin for inhibiting self-renewal of colorectal cancer stem cells (CSCs)." | 4.31 | [Metformin inhibits self-renewal of colorectal cancer stem cells by inhibiting mitochondrial oxidative phosphorylation]. ( Hu, Y; Liu, S; Song, Q; Yan, C, 2023) |
| "This present study aims to explore the influence of metformin and postoperative insulin pump use on colorectal cancer (CRC) patients with type II diabetes mellitus (T2DM) who received surgery in terms of short-term and long-term outcomes." | 4.31 | The Use of Metformin and Postoperative Insulin Pump Were Predictive Factors for Outcomes of Diabetic Colorectal Cancer Patients after Surgery. ( Li, LS; Li, ZW; Liu, F; Liu, XR; Lv, Q; Peng, D; Shu, XP; Tong, Y; Zhang, W, 2023) |
| " Metformin may decrease the overall incidence of cancer in patients with diabetes and may decrease the incidence of colorectal cancer." | 4.12 | Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas. ( Abrams, JA; Araujo, JL; Buitrago, C; Huang, CH; Karkenny, G; Krigel, A; Lebwohl, B; Nguyen, STT; Talukder, N, 2022) |
| "Metformin inhibits oxidative phosphorylation and can be used to dissect metabolic pathways in colorectal cancer (CRC) cells." | 4.12 | A functional screen with metformin identifies microRNAs that regulate metabolism in colorectal cancer cells. ( Ali, SR; Aloia, AL; McKinnon, RA; Michael, MZ; Orang, A; Petersen, J, 2022) |
| "Multiple evidence shows that metformin serves as a potential agent for Colorectal Cancer (CRC) treatment, while its molecular mechanisms still require detailed investigation." | 4.12 | Metformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-β/PI3K/AKT signaling transduction. ( Liu, J; Shu, G; Xiao, J; Xiao, Q; Yin, G, 2022) |
| "Evidence from previous studies suggests a protective effect of metformin in patients with colorectal cancer (CRC)." | 4.12 | The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus. ( Christou, N; Jost, J; Magne, J; Manceur, K; Mathonnet, M; Tarhini, Z, 2022) |
| "Pre-diagnostic use of metformin and TTh were, independently and jointly, inversely associated with incident prostate and colorectal cancers." | 4.12 | Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men. ( Alzweri, L; Baillargeon, J; Canfield, S; Kristen Peek, M; Kuo, YF; Lopez, DS; Malagaris, I; Milani, SA; Polychronopoulou, E; Tsilidis, KK; Villasante-Tezanos, A, 2022) |
| "This study aimed to investigate the association between metformin usage and the risk of colorectal cancer (CRC) using data from the Korean National Health Insurance Service-National Health Screening Cohort database." | 4.02 | Metformin usage and the risk of colorectal cancer: a national cohort study. ( Bae, YJ; Choi, EA; Han, YE; Kang, HT; Kim, HS; Kim, J; Kim, Y; Kim, YS; Lee, JW; You, HS, 2021) |
| " Each 10% increase in 1-year adherence to metformin reduced cancer-specific mortality among women with breast cancer (adjusted HR = 0." | 4.02 | Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study. ( Feng, JL; Qin, X, 2021) |
| "We aimed to estimate colorectal cancer risk in patients with type 2 diabetes mellitus (T2DM) using metformin." | 3.96 | Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: national cohort study. ( Dulskas, A; Linkeviciute-Ulinskiene, D; Patasius, A; Smailyte, G; Urbonas, V; Zabuliene, L, 2020) |
| "To investigate the association between use of insulin or metformin with colorectal cancer (CRC) in type 2 diabetes (T2DM)." | 3.96 | Insulin enhances and metformin reduces risk of colorectal carcinoma in type-2 diabetes. ( Chen, CH; Hsu, CY; Kao, CH; Lin, CL, 2020) |
| "Epidemiological evidence for the association between postdiagnostic metformin use and survival in patients with colorectal cancer (CRC) remains limited." | 3.96 | Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study. ( Chang, JW; Chang, SH; Chen, JS; Chou, WC; Hsu, HC; Huang, WK; Kuo, CF; Lin, YC; See, LC; Yang, TS, 2020) |
| "Metformin use prior to diagnosis of cancer was associated with a decrease in risk of both breast cancer (OR = 0." | 3.96 | Use of metformin and risk of breast and colorectal cancer. ( Gronich, N; Gruber, SB; Pinchev, M; Rennert, G; Rennert, HS, 2020) |
| "Metformin may be a radiotherapy adjuvant agent for colorectal cancers especially those carrying P53 mutation." | 3.96 | Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy. ( Chen, L; Chen, Z; Gan, Y; Jiang, Q; Jiang, Z; Leng, Y; Li, X; Liao, F; Liu, D; Liu, Y; Luo, M; Luo, P; Ma, L; Shen, G; Shi, C; Tan, X; Wang, Q; Wang, Y; Wang, Z; Wu, J; Zhang, C, 2020) |
| "Accumulating evidence suggests that metformin reduces the incidence and mortality of colorectal cancer (CRC)." | 3.96 | Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. ( Horie, H; Kawahira, H; Kitayama, J; Koinuma, K; Lefor, AK; Mimura, T; Ohzawa, H; Saito, A; Sata, N; Yamaguchi, H, 2020) |
| "The purpose of this study was to investigate the effect of metformin or the combination of metformin and 5-FU on the growth and metastasis of colorectal cancer (CRC)." | 3.96 | Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU. ( Sang, J; Sun, Q; Tang, R; Yang, M, 2020) |
| "Metformin may be associated with reduced colorectal cancer (CRC) risk, but findings from previous studies have been inconsistent and had insufficient sample sizes to examine whether the association differs by anatomic site." | 3.91 | Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes. ( Bustamante, R; Demb, J; Earles, A; Gawron, AJ; Ghosh, P; Gupta, S; Gutkind, JS; Kaltenbach, TR; Liu, L; Martinez, ME; Yaseyyedi, A, 2019) |
| "The present study aimed to examine the roles and mechanisms of metformin in the stemness and epithelial‑mesenchymal transition (EMT) of colorectal cancer cells." | 3.91 | Metformin attenuates cells stemness and epithelial‑mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β‑catenin pathway. ( Wang, Y; Zhang, C, 2019) |
| " In this study, we describe the inhibitory effect of metformin in interleukin 8 (IL-8) upregulation by lithocholic acid (LCA) in HCT116 colorectal cancer (CRC) cells." | 3.91 | Metformin inhibits lithocholic acid-induced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity. ( Do Jung, Y; Li, S; Lian, S; Nguyen, TT; Park, SY; Ung, TT; Xia, Y, 2019) |
| "Precision medicine might be the response to the recent questioning of the use of metformin as an anticancer drug in colorectal cancer (CRC)." | 3.91 | A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment. ( Cruz-Gil, S; Pape, K; Ramírez de Molina, A; Sánchez-Martínez, R; Schölch, S; Stange, D; Wagner-Reguero, S, 2019) |
| " In this commentary, using the study of metformin use on colorectal cancer risk by Bradley and colleagues (2018) as motivation, we compare the etiologic versus action-focused analysis of epidemiologic data." | 3.88 | Studying the Effects of Nonindicated Medications on Cancer: Etiologic versus Action-Focused Analysis of Epidemiologic Data. ( García-Albéniz, X; Jackson, JW, 2018) |
| " Here, we proposed to assess the anti-EMT abilities and explore the inherent pharmacological mechanisms of the classic hypoglycaemic agent metformin for colorectal cancer(CRC)." | 3.88 | The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC). ( Hu, L; Wang, Y; Wu, Z, 2018) |
| "Purpose Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients with colorectal cancer (CRC) and type II diabetes mellitus (DM)." | 3.88 | Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer. ( Abdelkhaleq, H; Al Omari, A; Al-Hussaini, M; Alfaqih, MA; Awad, N; Garrett, CR; Hassan, MM; Turfa, R, 2018) |
| "The antidiabetic drug metformin has been associated with reduced colorectal cancer (CRC) risk and improved prognosis of CRC patients." | 3.88 | Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling. ( Calin, GA; Chen, M; Knutsen, E; Ling, H; Pichler, M; Reineke, LC; Shen, P, 2018) |
| "Metformin, a first-line drug used to treat type 2 diabetes, has also been shown to have anticancer effects against a variety of malignancies, including colorectal cancer." | 3.88 | Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells. ( Kang, MH; Kang, S; Kim, BR; Kim, DY; Lee, DH; Min, BW; Oh, SC; Um, JW, 2018) |
| "The association between metformin and colorectal cancer (CRC) has rarely been investigated in Asian populations." | 3.85 | Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis. ( Tseng, CH, 2017) |
| "To assess factors associated with the higher effect of metformin on mortality in diabetic colorectal cancer (CRC) patients, since the factors related to the effectiveness of metformin have not been identified yet." | 3.85 | Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. ( Cheon, JH; Kim, TI; Kim, WH; Lee, JH; Park, JW; Park, SJ; Park, YH, 2017) |
| "The function of metformin in colorectal cancer (CRC) patients with diabetes mellitus (DM) remains a controversial topic because studies are increasingly focusing on epidemiologic features." | 3.85 | Metformin depresses overactivated Notch1/Hes1 signaling in colorectal cancer patients with type 2 diabetes mellitus. ( Chen, S; Han, FH; Huang, CZ; Liu, GJ; Liu, Q; Yang, B; Yu, T; Zhou, SN, 2017) |
| "Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer." | 3.85 | The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. ( Cheon, JH; Han, MS; Hong, SP; Kim, TI; Kim, WH; Lee, HJ; Park, SJ, 2017) |
| "Emerging evidence suggests that metformin decreases the risk of developing colorectal cancer in patients with diabetes, but only few studies have examined potential survival benefits after surgery for colorectal cancer (CRC)." | 3.83 | Metformin Increases Overall Survival in Patients with Diabetes Undergoing Surgery for Colorectal Cancer. ( Fransgaard, T; Gögenur, I; Thygesen, LC, 2016) |
| "Metformin has been associated with improved colorectal cancer survival, but investigations are limited by small numbers of patients and confounding by diabetic severity." | 3.83 | Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. ( Cossor, FI; Kelley, MJ; Martell, RE; Paulus, JK; Williams, CD, 2016) |
| "Emerging evidence from observational studies has suggested that metformin may be beneficial in the primary prevention of colorectal cancer (CRC)." | 3.81 | Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. ( Bissonnette, MB; Olopade, OI; Polite, BN; Sehdev, A; Shih, YC; Vekhter, B, 2015) |
| "To investigate the effect of metformin on silibinin-induced apoptosis in human colorectal cancer (COLO 205) cells." | 3.81 | Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells. ( Chen, LJ; Cheng, JT; Chuang, TW; Chung, KM; Lin, KC; Niu, HS; Tsai, CC, 2015) |
| "Existing literature suggests that metformin, the most commonly used biguanide, may lower colorectal cancer risk." | 3.81 | Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. ( Corley, DA; Doubeni, CA; Jensen, CD; Marks, AR; Pietrofesa, RA; Zebrowski, A, 2015) |
| "The present study addressed whether the combination of metformin and ionizing radiation (IR) would show enhanced antitumor effects in radioresistant p53-deficient colorectal cancer cells, focusing on repair pathways for IR-induced DNA damage." | 3.81 | Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins. ( Ha, H; Jeong, YK; Kim, EH; Kim, MS; Lee, JY, 2015) |
| "While overall there was no statistically significant association between metformin exposure and disseminated colorectal cancer at diagnosis, there was a suggestion that high intensity, exclusive metformin use may be associated with reduced odds of disseminated disease." | 3.80 | Metformin exposure and disseminated disease in patients with colorectal cancer. ( Barron, TI; Bennett, K; Sharp, L; Spillane, S, 2014) |
| "In vitro and animal studies indicate that metformin prevents colorectal cancer (CRC)." | 3.80 | Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. ( Cardel, M; Hallas, J; Jensen, SM; Jørgensen, TL; Pottegård, A, 2014) |
| "Preclinical evidence suggests a beneficial effect of metformin in colorectal cancer." | 3.79 | A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. ( Barron, TI; Bennett, K; Sharp, L; Spillane, S, 2013) |
| "Observational studies have associated metformin use with lower colorectal cancer (CRC) incidence but few studies have examined metformin's influence on CRC survival." | 3.79 | Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. ( Adams-Campbell, LL; Chlebowski, RT; Cossor, FI; Gunter, MJ; Johnson, K; Martell, RE; McTiernan, A; Paulus, JK; Rohan, T; Simon, MS; Wallace, RB, 2013) |
| "Experimental studies have suggested that metformin may decrease the incidence of colorectal cancer in patients with type II diabetes." | 3.79 | The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. ( Azoulay, L; Pollak, MN; Smiechowski, B; Suissa, S; Yin, H, 2013) |
| "In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality." | 3.79 | Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013) |
| "To explore the association between use of metformin or other antidiabetic drugs and the risk of colorectal cancer." | 3.78 | Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. ( Becker, C; Bodmer, M; Jick, SS; Meier, C; Meier, CR, 2012) |
| "Colorectal cancer patients with DM treated with metformin as part of their diabetic therapy appear to have a superior OS." | 3.78 | Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. ( Baladandayuthapani, V; Bhadkamkar, NA; Eng, C; Garrett, CR; Hassabo, HM; Hassan, MM; Kee, BK; Wen, S, 2012) |
| "This study aimed to evaluate the potential effect of metformin on the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer." | 3.78 | Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "Inflammation is one biological mechanism hypothesized to mediate these associations." | 2.94 | Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. ( Abrams, TA; Brown, JC; Campbell, N; Cartmel, B; Douglas, PS; Fuchs, CS; Harrigan, M; Hu, FB; Irwin, ML; Jones, LW; Ligibel, JA; Meyerhardt, JA; Ng, K; Pollak, MN; Sanft, T; Sorrentino, A; Tolaney, SM; Winer, EP; Zhang, S, 2020) |
| "The incidence and mortality rates of colorectal cancer (CRC) continue to increase worldwide." | 2.94 | The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial. ( Arimoto, J; Ashikari, K; Fuyuki, A; Higurashi, T; Matsuura, T; Misawa, N; Nakajima, A; Ohkubo, H; Takatsu, T; Yoshihara, T, 2020) |
| "GDF-15 was not associated with type 2 diabetes, glycaemic traits, CAD risk factors or colorectal cancer." | 2.90 | The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. ( Au Yeung, SL; Luo, S; Schooling, CM, 2019) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 2.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "Colorectal cancer is one of the major neoplasms and a leading cause of cancer death worldwide, and new preventive strategies are needed to lower the burden of this disease." | 2.77 | Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. ( Endo, H; Ezuka, A; Fujisawa, N; Hata, Y; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Matsuhashi, N; Morita, S; Nagase, H; Nakajima, A; Ohkubo, H; Sakai, E; Takahashi, H; Uchiyama, S; Uchiyama, T; Yamada, E; Yamanaka, S, 2012) |
| "Metformin, a biguanide, has been widely used in treating diabetes." | 2.61 | Metformin: A Salutary Candidate for Colorectal Cancer Treatment in Patients with Diabetes. ( Chellappan, DK; Dahiya, R; Dua, K; Gubbiyappa, SK; Gupta, G; Sah, SK; Samuel, VP; Singh, Y, 2019) |
| "Studies on patients with type 2 diabetes treated with metformin analyzed data on total of 146 496 patients." | 2.61 | Metformin and Colorectal Cancer - A Systematic Review. ( Dobrzycka, M; Jędrusik, P; Kobiela, J; Kobiela, P; Śledziński, Z; Spychalski, P; Zdrojewski, T, 2019) |
| "Diabetic patients have a higher risk of colorectal cancer (CRC)." | 2.53 | Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. ( Gu, M; Nie, Z; Zhu, H, 2016) |
| "Colorectal cancer is the most intensively studied cancer because of its high incidence and mortality rate." | 2.50 | Targeting mTOR network in colorectal cancer therapy. ( Wang, XW; Zhang, YJ, 2014) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "Colorectal cancer is the third leading cause of cancer death in Japan and the United States and is strongly associated with obesity, especially visceral obesity." | 2.49 | Colon epithelial proliferation and carcinogenesis in diet-induced obesity. ( Endo, H; Hosono, K; Nakajima, A; Takahashi, H, 2013) |
| "Colorectal cancer is the fourth most common cancer in the world." | 2.48 | Chemoprevention in colorectal cancer--where we stand and what we have learned from twenty year's experience. ( Boghossian, S; Hawash, A, 2012) |
| "Colorectal carcinoma is a tumour with higher incidence in patients with type 2 diabetes and obesity." | 2.47 | [Colorectal cancer and diabetes]. ( Svacina, S, 2011) |
| "Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes." | 1.72 | The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022) |
| "But its role in the development of colorectal cancer (CRC) cancer remains unknown." | 1.72 | FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. ( Deng, H; He, Z; Li, G; Mou, T; Shi, J; Sui, C; Sun, K; Wang, T; Wang, Y; Xu, Z; Yang, J; Zhang, P; Zhuang, B, 2022) |
| "Metformin may reduce colorectal cancer but the mechanisms mediating this effect remain unclear." | 1.72 | Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. ( Bezverbnaya, K; Blandino, G; Blouin, MJ; Bramson, JL; Broadfield, LA; Collins, SM; Di Pastena, F; Gautam, J; Hammill, JA; Lally, JSV; McArthur, AG; McNicol, J; Muti, P; Pollak, M; Raphenya, AR; Sacconi, A; Saigal, A; Schertzer, JD; Steinberg, GR; Surette, MG; Syed, S; Szamosi, JC; Tsakiridis, EE; Tsakiridis, T; Wang, D; Wu, J, 2022) |
| "The association between type 2 diabetes mellitus (DM) and colorectal cancer (CRC) has been thoroughly investigated and reports have demonstrated that the risk of CRC is increased in DM patients." | 1.72 | Effects of diabetes type 2 and metformin treatment in Swedish patients with colorectal cancer. ( Dimberg, J; Landerholm, K; Shamoun, L; Wågsäter, D, 2022) |
| "Metformin is a commonly used drug for the treatment of diabetes." | 1.72 | Metformin inhibits the development and metastasis of colorectal cancer. ( Hasegawa, H; Ishida, T; Kitagawa, Y; Okabayashi, K; Seishima, R; Shigeta, K; Sugiura, K; Tsuruta, M, 2022) |
| "Metformin (MT) was recently approved as anticancer drug against solid tumors, such as CRC." | 1.62 | Metformin-loaded lecithin nanoparticles induce colorectal cancer cytotoxicity via epigenetic modulation of noncoding RNAs. ( Abd-Rabou, AA; Abdelaziz, AM; Ayeldeen, G; Shaker, OG, 2021) |
| "We used two colorectal cancer cell lines with different growth rates and clinically achievable metformin concentrations." | 1.62 | Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells. ( Alhourani, AH; Bokil, AA; Hagland, HR; Røsland, GV; Søreide, K; Tidwell, TR; Tronstad, KJ, 2021) |
| "Metformin and cisplatin have been widely studied as antitumor agents." | 1.56 | Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway. ( Liu, H; Lu, X; Shi, Z; Zhang, P; Zhao, S; Zhu, B, 2020) |
| "The occurrence of colorectal cancer (CRC) is associated with a variety of oncogenes and tumor‑suppressor genes." | 1.51 | Molecular mechanism of LKB1 in the invasion and metastasis of colorectal cancer. ( Chen, Y; Liu, Y; You, H; Zhou, Y, 2019) |
| "Metformin has been known to suppress cancer stem cells (CSCs) in some cancers." | 1.48 | Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. ( Cheon, JH; Hong, SP; Il Kim, T; Kang, JY; Kim, JH; Kim, WH; Kwon, JH; Lee, HJ; Lee, KJ; Park, SJ; Seo, Y; Yoon, JP, 2018) |
| "Metformin is a promising drug for cancer prevention and treatment, especially in the diabetic population." | 1.48 | 14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. ( Chen, Y; Cheng, K; Ding, J; Du, Y; Li, ZK; Liu, JQ; Liu, JY; Qiu, M; Tang, J; Wang, YY; Yang, L; Zhang, YN; Zhu, YT, 2018) |
| "Metformin treatment has been associated with a reduced risk of developing cancer, but whether metformin influences the risk of recurrence is unknown." | 1.48 | Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study. ( Fransgaard, T; Gögenur, I; Thygesen, LC, 2018) |
| "With no sharp cure, breast cancer still be the major and the most serious life-threatening disease worldwide." | 1.48 | Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells ( Abdel-Ghany, SE; El-Zawahry, M; M Said, OA; Mostafa, MA; Sabit, H, 2018) |
| "The CRC colorectal cancer (CRC) cell lines HCT116 wild-type (wt), HCT116 p53-/-, and HT-29 (mutant; R273H) were employed, covering three different p53 variations." | 1.46 | Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells. ( Abu El Maaty, MA; Dabiri, Y; Qaiser, T; Strassburger, W; Wölfl, S, 2017) |
| "Metformin is a widely used and well-tolerated anti-diabetic drug that can reduce cancer risk and improve the prognosis of certain malignancies." | 1.46 | Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. ( Belfiore, A; Bozzi, F; Gariboldi, M; Gloghini, A; Maiorana, MV; Mogavero, A; Pierotti, MA; Varinelli, L; Volpi, CC; Zanutto, S, 2017) |
| "Metformin use was identified from CPRD prescription records." | 1.43 | Metformin use and survival after colorectal cancer: A population-based cohort study. ( Cardwell, CR; Hughes, CM; Mc Menamin, ÚC; Murray, LJ, 2016) |
| "Metformin is an anti-diabetic drug with a promising anti-cancer potential." | 1.43 | Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. ( Jeong, YA; Jo, MJ; Kim, BR; Kim, JL; Lee, DH; Lee, SI; Lee, SY; Lee, YY; Na, YJ; Oh, SC; Park, SH, 2016) |
| "Medical records of 1087 patients with type 2 diabetes were retrospectively analyzed and a group of 74 (6." | 1.42 | [Obesity as a factor in the development of cancer in type 2 diabetes]. ( Chodorowska, M; Jakubowska, I; Łukasiewicz, D, 2015) |
| "Metformin treatment significantly improved tumor oxygenation in two xenograft models as measured by IHC, flow cytometry, and PET imaging." | 1.39 | Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. ( Bristow, RG; Chaib, S; Dal Pra, A; Glicksman, R; Koritzinsky, M; McKee, TD; Milosevic, M; Muaddi, H; Stapleton, S; Sykes, J; Wouters, BG; Zamiara, P; Zannella, VE, 2013) |
| "New diagnoses of cancer, including malignant solid tumours and haematological malignancies, occurring during the follow-up were identified from the cohort." | 1.39 | Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. ( Berlin, JA; Demissie, K; Marcella, SW; Qiu, H; Rhoads, GG, 2013) |
| "Metformin use was associated with decreased overall mortality (p = 0." | 1.38 | The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "Metformin is known to lower the risk of cancer and cancer mortality." | 1.38 | [The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes]. ( Cheon, JH; Hong, SP; Kim, B; Kim, TI; Kim, WH; Lee, DJ; Lee, JH; Park, SJ, 2012) |
| " The covariates included age, gender, other oral anti-hyperglycemic medication, Charlson comorbidity index (CCI) score and metformin exposure dosage and duration." | 1.37 | Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. ( Chang, YH; Hsu, CC; Huang, YC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011) |
| "Treatment with metformin significantly reduced ACF formation." | 1.36 | Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. ( Chihara, T; Endo, H; Fujita, K; Hosono, K; Inamori, M; Nakagama, H; Nakajima, A; Nozaki, Y; Shimpo, K; Sugiyama, M; Suzuki, K; Takahashi, H; Tomatsu, A; Uchiyama, T; Yoneda, K; Yoneda, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.61) | 29.6817 |
| 2010's | 104 (63.03) | 24.3611 |
| 2020's | 60 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Abd-Rabou, AA | 1 |
| Abdelaziz, AM | 1 |
| Shaker, OG | 1 |
| Ayeldeen, G | 1 |
| Wang, Q | 2 |
| Shi, M | 1 |
| Ala, M | 1 |
| Krigel, A | 1 |
| Nguyen, STT | 1 |
| Talukder, N | 1 |
| Huang, CH | 1 |
| Buitrago, C | 1 |
| Karkenny, G | 1 |
| Lebwohl, B | 1 |
| Abrams, JA | 1 |
| Araujo, JL | 1 |
| Orang, A | 1 |
| Ali, SR | 1 |
| Petersen, J | 2 |
| McKinnon, RA | 1 |
| Aloia, AL | 1 |
| Michael, MZ | 2 |
| Arai, J | 1 |
| Suzuki, N | 1 |
| Niikura, R | 1 |
| Ooki, D | 1 |
| Kawahara, T | 1 |
| Honda, T | 1 |
| Hasatani, K | 1 |
| Yoshida, N | 1 |
| Nishida, T | 1 |
| Sumiyoshi, T | 1 |
| Kiyotoki, S | 1 |
| Ikeya, T | 1 |
| Arai, M | 1 |
| Ishibashi, R | 1 |
| Aoki, T | 1 |
| Tsuji, Y | 1 |
| Yamamichi, N | 1 |
| Hayakawa, Y | 1 |
| Fujishiro, M | 1 |
| Xiao, Q | 1 |
| Xiao, J | 2 |
| Liu, J | 4 |
| Shu, G | 1 |
| Yin, G | 1 |
| Jiang, S | 1 |
| Lu, Q | 1 |
| He, Z | 1 |
| Yang, J | 2 |
| Sui, C | 1 |
| Zhang, P | 3 |
| Wang, T | 2 |
| Mou, T | 1 |
| Sun, K | 1 |
| Wang, Y | 5 |
| Xu, Z | 1 |
| Li, G | 1 |
| Deng, H | 1 |
| Shi, J | 1 |
| Zhuang, B | 1 |
| Broadfield, LA | 1 |
| Saigal, A | 1 |
| Szamosi, JC | 1 |
| Hammill, JA | 1 |
| Bezverbnaya, K | 1 |
| Wang, D | 1 |
| Gautam, J | 1 |
| Tsakiridis, EE | 1 |
| Di Pastena, F | 1 |
| McNicol, J | 1 |
| Wu, J | 3 |
| Syed, S | 1 |
| Lally, JSV | 1 |
| Raphenya, AR | 1 |
| Blouin, MJ | 1 |
| Pollak, M | 1 |
| Sacconi, A | 1 |
| Blandino, G | 1 |
| McArthur, AG | 1 |
| Schertzer, JD | 1 |
| Surette, MG | 1 |
| Collins, SM | 1 |
| Bramson, JL | 1 |
| Muti, P | 1 |
| Tsakiridis, T | 1 |
| Steinberg, GR | 1 |
| Dimberg, J | 1 |
| Shamoun, L | 1 |
| Landerholm, K | 1 |
| Wågsäter, D | 1 |
| Nittayaboon, K | 1 |
| Leetanaporn, K | 1 |
| Sangkhathat, S | 1 |
| Roytrakul, S | 1 |
| Navakanitworakul, R | 1 |
| Sun, C | 1 |
| Yang, X | 2 |
| Jin, Z | 1 |
| Gao, Z | 1 |
| Sugiura, K | 1 |
| Okabayashi, K | 1 |
| Seishima, R | 1 |
| Ishida, T | 1 |
| Shigeta, K | 1 |
| Tsuruta, M | 1 |
| Hasegawa, H | 1 |
| Kitagawa, Y | 1 |
| Zhang, HS | 1 |
| Yang, Y | 1 |
| Lee, S | 1 |
| Park, S | 1 |
| Nam, CM | 1 |
| Jee, SH | 1 |
| Tarhini, Z | 1 |
| Manceur, K | 1 |
| Magne, J | 1 |
| Mathonnet, M | 1 |
| Jost, J | 1 |
| Christou, N | 1 |
| Lopez, DS | 1 |
| Malagaris, I | 1 |
| Polychronopoulou, E | 1 |
| Tsilidis, KK | 1 |
| Milani, SA | 1 |
| Kristen Peek, M | 1 |
| Villasante-Tezanos, A | 1 |
| Alzweri, L | 1 |
| Baillargeon, J | 1 |
| Kuo, YF | 1 |
| Canfield, S | 1 |
| Ni, W | 1 |
| Feng, Y | 1 |
| Hu, Y | 2 |
| Liu, H | 2 |
| Chen, J | 3 |
| Chen, F | 1 |
| Tian, H | 1 |
| Song, L | 2 |
| Hao, Y | 1 |
| Wang, C | 1 |
| Han, Y | 1 |
| Zhu, Y | 1 |
| Feng, L | 1 |
| Miao, L | 1 |
| Liu, Z | 1 |
| Shami, JJP | 3 |
| Yan, VKC | 3 |
| Wei, Y | 3 |
| Alwafi, H | 3 |
| Blais, JE | 3 |
| Wan, E | 3 |
| Wong, CKH | 3 |
| Cheung, KS | 3 |
| Leung, WK | 3 |
| Wong, MCS | 3 |
| Wong, ICK | 3 |
| Chan, EW | 3 |
| Salovska, B | 1 |
| Gao, E | 1 |
| Müller-Dott, S | 1 |
| Li, W | 3 |
| Cordon, CC | 1 |
| Wang, S | 1 |
| Dugourd, A | 1 |
| Rosenberger, G | 1 |
| Saez-Rodriguez, J | 1 |
| Liu, Y | 5 |
| Morrison, KR | 1 |
| Chan, KY | 1 |
| Trotter, EW | 1 |
| Gillespie, A | 1 |
| Oakhill, JS | 1 |
| Hagan, IM | 1 |
| Chu, PT | 1 |
| Chuang, TJ | 1 |
| Huang, SH | 1 |
| Wu, TH | 1 |
| Huang, WC | 1 |
| Wang, JH | 1 |
| Huang, X | 1 |
| Sun, T | 1 |
| Wang, J | 1 |
| Hong, X | 1 |
| Chen, H | 1 |
| Yan, T | 1 |
| Zhou, C | 2 |
| Sun, D | 1 |
| Yang, C | 1 |
| Yu, T | 2 |
| Su, W | 1 |
| Du, W | 1 |
| Xiong, H | 2 |
| Vedire, YR | 1 |
| Mukherjee, S | 1 |
| Dondapati, S | 1 |
| Yendamuri, S | 1 |
| Luo, Z | 1 |
| Wang, B | 1 |
| Luo, F | 1 |
| Guo, Y | 1 |
| Jiang, N | 1 |
| Wei, J | 1 |
| Wang, X | 3 |
| Tseng, Y | 1 |
| Zhao, B | 1 |
| Yan, C | 1 |
| Liu, S | 1 |
| Song, Q | 1 |
| Huang, Y | 1 |
| Wang, F | 2 |
| Lin, X | 1 |
| Li, Q | 1 |
| Lu, Y | 2 |
| Zhang, J | 2 |
| Shen, X | 1 |
| Tan, J | 1 |
| Qin, Z | 1 |
| Chen, X | 1 |
| Pan, G | 1 |
| Zeng, Y | 1 |
| Yang, S | 2 |
| Xing, F | 1 |
| Li, K | 1 |
| Zhang, H | 2 |
| Akce, M | 1 |
| Farran, B | 1 |
| Switchenko, JM | 1 |
| Rupji, M | 1 |
| Kang, S | 2 |
| Khalil, L | 1 |
| Ruggieri-Joyce, A | 1 |
| Olson, B | 1 |
| Shaib, WL | 1 |
| Wu, C | 1 |
| Alese, OB | 1 |
| Diab, M | 1 |
| Lesinski, GB | 1 |
| El-Rayes, BF | 1 |
| Liu, XR | 1 |
| Liu, F | 2 |
| Li, ZW | 1 |
| Lv, Q | 1 |
| Shu, XP | 1 |
| Li, LS | 1 |
| Tong, Y | 1 |
| Zhang, W | 2 |
| Peng, D | 1 |
| Dulskas, A | 2 |
| Patasius, A | 2 |
| Linkeviciute-Ulinskiene, D | 2 |
| Zabuliene, L | 2 |
| Urbonas, V | 2 |
| Smailyte, G | 2 |
| Chen, CH | 1 |
| Lin, CL | 1 |
| Hsu, CY | 1 |
| Kao, CH | 1 |
| Samuel, VP | 1 |
| Dahiya, R | 1 |
| Singh, Y | 1 |
| Gupta, G | 1 |
| Sah, SK | 1 |
| Gubbiyappa, SK | 1 |
| Chellappan, DK | 1 |
| Dua, K | 1 |
| Mormile, R | 2 |
| Demb, J | 1 |
| Yaseyyedi, A | 1 |
| Liu, L | 1 |
| Bustamante, R | 1 |
| Earles, A | 1 |
| Ghosh, P | 1 |
| Gutkind, JS | 1 |
| Gawron, AJ | 1 |
| Kaltenbach, TR | 1 |
| Martinez, ME | 1 |
| Gupta, S | 1 |
| Deng, M | 1 |
| Lei, S | 1 |
| Huang, D | 1 |
| Wang, H | 1 |
| Xia, S | 1 |
| Xu, E | 1 |
| Wu, Y | 1 |
| Kamarudin, MNA | 1 |
| Sarker, MMR | 1 |
| Zhou, JR | 1 |
| Parhar, I | 1 |
| Zhao, Y | 1 |
| Du, S | 1 |
| Du, J | 1 |
| Huang, WK | 1 |
| Chang, SH | 1 |
| Hsu, HC | 1 |
| Chou, WC | 1 |
| Yang, TS | 1 |
| Chen, JS | 1 |
| Chang, JW | 1 |
| Lin, YC | 1 |
| Kuo, CF | 1 |
| See, LC | 1 |
| Zhao, S | 1 |
| Lu, X | 1 |
| Shi, Z | 1 |
| Zhu, B | 1 |
| Xie, J | 1 |
| Xia, L | 1 |
| Xiang, W | 1 |
| He, W | 1 |
| Yin, H | 2 |
| Gao, T | 1 |
| Qi, W | 1 |
| Yang, Z | 1 |
| Zhou, T | 1 |
| Gao, G | 1 |
| Rennert, G | 1 |
| Rennert, HS | 1 |
| Gronich, N | 1 |
| Pinchev, M | 1 |
| Gruber, SB | 1 |
| Chen, L | 1 |
| Liao, F | 1 |
| Jiang, Z | 1 |
| Zhang, C | 2 |
| Wang, Z | 2 |
| Luo, P | 1 |
| Jiang, Q | 1 |
| Luo, M | 1 |
| Li, X | 2 |
| Leng, Y | 1 |
| Ma, L | 2 |
| Shen, G | 1 |
| Chen, Z | 1 |
| Tan, X | 1 |
| Gan, Y | 1 |
| Liu, D | 1 |
| Shi, C | 1 |
| Jones, GR | 1 |
| Molloy, MP | 1 |
| Ng, CW | 1 |
| Jiang, AA | 1 |
| Toh, EMS | 1 |
| Ng, CH | 1 |
| Ong, ZH | 1 |
| Peng, S | 2 |
| Tham, HY | 1 |
| Sundar, R | 1 |
| Chong, CS | 1 |
| Khoo, CM | 1 |
| Yang, WT | 1 |
| Yang, HJ | 1 |
| Zhou, JG | 1 |
| Liu, JL | 1 |
| Saito, A | 1 |
| Kitayama, J | 1 |
| Horie, H | 1 |
| Koinuma, K | 1 |
| Ohzawa, H | 1 |
| Yamaguchi, H | 1 |
| Kawahira, H | 1 |
| Mimura, T | 1 |
| Lefor, AK | 1 |
| Sata, N | 1 |
| Sang, J | 1 |
| Tang, R | 1 |
| Yang, M | 1 |
| Sun, Q | 1 |
| Brown, JC | 1 |
| Zhang, S | 1 |
| Ligibel, JA | 1 |
| Irwin, ML | 1 |
| Jones, LW | 1 |
| Campbell, N | 1 |
| Pollak, MN | 2 |
| Sorrentino, A | 1 |
| Cartmel, B | 1 |
| Harrigan, M | 1 |
| Tolaney, SM | 1 |
| Winer, EP | 1 |
| Ng, K | 1 |
| Abrams, TA | 1 |
| Sanft, T | 1 |
| Douglas, PS | 1 |
| Hu, FB | 1 |
| Fuchs, CS | 1 |
| Meyerhardt, JA | 1 |
| Lee, JW | 1 |
| Choi, EA | 1 |
| Kim, YS | 1 |
| Kim, Y | 1 |
| You, HS | 1 |
| Han, YE | 1 |
| Kim, HS | 1 |
| Bae, YJ | 1 |
| Kim, J | 1 |
| Kang, HT | 1 |
| Higurashi, T | 3 |
| Arimoto, J | 2 |
| Ashikari, K | 1 |
| Takatsu, T | 1 |
| Misawa, N | 1 |
| Yoshihara, T | 1 |
| Matsuura, T | 1 |
| Fuyuki, A | 1 |
| Ohkubo, H | 2 |
| Nakajima, A | 6 |
| Bragagnoli, AC | 2 |
| Araujo, RLC | 1 |
| Ferraz, MW | 1 |
| Dos Santos, LV | 1 |
| Abdalla, KC | 1 |
| Comar, F | 1 |
| Santos, FA | 1 |
| Oliveira, MA | 1 |
| Carvalheira, JBC | 2 |
| Cárcano, FM | 1 |
| da Silveira Nogueira Lima, JP | 1 |
| Salgado-García, R | 1 |
| Coronel-Hernández, J | 1 |
| Delgado-Waldo, I | 1 |
| Cantú de León, D | 1 |
| García-Castillo, V | 1 |
| López-Urrutia, E | 1 |
| Gutiérrez-Ruiz, MC | 1 |
| Pérez-Plasencia, C | 1 |
| Jacobo-Herrera, N | 1 |
| Jaromy, M | 1 |
| Miller, JD | 1 |
| Niculescu, DA | 1 |
| Feng, JL | 1 |
| Qin, X | 1 |
| Anselmino, LE | 1 |
| Baglioni, MV | 1 |
| Malizia, F | 1 |
| Laluce, NC | 1 |
| Etichetti, CB | 1 |
| Marignac, VLM | 1 |
| Rozados, V | 1 |
| Scharovsky, OG | 1 |
| Girardini, J | 1 |
| Rico, MJ | 1 |
| Menacho Márquez, M | 1 |
| Berkovic, MC | 1 |
| Mikulic, D | 1 |
| Bilic-Curcic, I | 1 |
| Mrzljak, A | 1 |
| Zhang, T | 1 |
| Hu, L | 2 |
| Tang, JF | 1 |
| Xu, H | 1 |
| Tian, K | 2 |
| Wu, MN | 1 |
| Huang, SY | 1 |
| Du, YM | 1 |
| Zhou, P | 1 |
| Lu, RJ | 1 |
| He, S | 2 |
| Xu, JM | 1 |
| Si, JJ | 1 |
| Li, J | 1 |
| Chen, DL | 1 |
| Ran, JH | 1 |
| Alhourani, AH | 1 |
| Tidwell, TR | 1 |
| Bokil, AA | 1 |
| Røsland, GV | 1 |
| Tronstad, KJ | 1 |
| Søreide, K | 1 |
| Hagland, HR | 1 |
| Cunha Júnior, AD | 1 |
| Costa, FO | 1 |
| Tseng, CH | 1 |
| Jung, YS | 1 |
| Park, CH | 1 |
| Eun, CS | 1 |
| Park, DI | 1 |
| Han, DS | 1 |
| Alam, NN | 1 |
| Badrick, E | 1 |
| Sperrin, M | 1 |
| Renehan, AG | 1 |
| Paulus, JK | 3 |
| Williams, CD | 2 |
| Cossor, FI | 3 |
| Kelley, MJ | 2 |
| Martell, RE | 3 |
| Abu El Maaty, MA | 1 |
| Strassburger, W | 1 |
| Qaiser, T | 1 |
| Dabiri, Y | 1 |
| Wölfl, S | 1 |
| Su, T | 1 |
| Liao, B | 1 |
| Dong, Y | 1 |
| Peng, Z | 1 |
| Zhou, Q | 1 |
| Li, B | 2 |
| Zhang, N | 1 |
| Park, JW | 1 |
| Lee, JH | 4 |
| Park, YH | 1 |
| Park, SJ | 4 |
| Cheon, JH | 6 |
| Kim, WH | 6 |
| Kim, TI | 6 |
| Fransgaard, T | 4 |
| Thygesen, LC | 4 |
| Gögenur, I | 5 |
| Mogavero, A | 1 |
| Maiorana, MV | 1 |
| Zanutto, S | 1 |
| Varinelli, L | 1 |
| Bozzi, F | 1 |
| Belfiore, A | 1 |
| Volpi, CC | 1 |
| Gloghini, A | 1 |
| Pierotti, MA | 1 |
| Gariboldi, M | 1 |
| Peng, WF | 1 |
| Bai, F | 1 |
| Shao, K | 1 |
| Shen, LS | 1 |
| Li, HH | 1 |
| Huang, S | 1 |
| Kim, JH | 1 |
| Lee, KJ | 1 |
| Seo, Y | 1 |
| Kwon, JH | 1 |
| Yoon, JP | 1 |
| Kang, JY | 1 |
| Lee, HJ | 2 |
| Hong, SP | 5 |
| Il Kim, T | 1 |
| Ding, J | 1 |
| Zhu, YT | 1 |
| Yang, L | 1 |
| Tang, J | 1 |
| Wang, YY | 1 |
| Chen, Y | 3 |
| Cheng, K | 1 |
| Liu, JQ | 1 |
| Zhang, YN | 1 |
| Li, ZK | 1 |
| Du, Y | 1 |
| Qiu, M | 1 |
| Liu, JY | 1 |
| Jackson, JW | 1 |
| García-Albéniz, X | 1 |
| Bradley, MC | 1 |
| Ferrara, A | 2 |
| Achacoso, N | 1 |
| Ehrlich, SF | 1 |
| Quesenberry, CP | 2 |
| Habel, LA | 2 |
| Huang, WS | 1 |
| Lin, CT | 1 |
| Chen, CN | 1 |
| Chang, SF | 1 |
| Chang, HI | 1 |
| Lee, KC | 1 |
| El-Fatatry, BM | 1 |
| Ibrahim, OM | 1 |
| Hussien, FZ | 1 |
| Mostafa, TM | 1 |
| Kobiela, J | 1 |
| Dobrzycka, M | 1 |
| Jędrusik, P | 1 |
| Kobiela, P | 1 |
| Spychalski, P | 1 |
| Śledziński, Z | 1 |
| Zdrojewski, T | 1 |
| Wu, Z | 1 |
| Al Omari, A | 1 |
| Abdelkhaleq, H | 1 |
| Al-Hussaini, M | 1 |
| Turfa, R | 1 |
| Awad, N | 1 |
| Hassan, MM | 2 |
| Alfaqih, MA | 1 |
| Garrett, CR | 2 |
| Saber, MM | 2 |
| Al-Mahallawi, AM | 1 |
| Nassar, NN | 1 |
| Stork, B | 1 |
| Shouman, SA | 2 |
| Shen, P | 1 |
| Reineke, LC | 1 |
| Knutsen, E | 1 |
| Chen, M | 1 |
| Pichler, M | 1 |
| Ling, H | 1 |
| Calin, GA | 1 |
| Kim, BR | 2 |
| Kang, MH | 1 |
| Kim, DY | 1 |
| Lee, DH | 2 |
| Oh, SC | 2 |
| Min, BW | 1 |
| Um, JW | 1 |
| Sabit, H | 1 |
| Abdel-Ghany, SE | 1 |
| M Said, OA | 1 |
| Mostafa, MA | 1 |
| El-Zawahry, M | 1 |
| Zhou, Y | 1 |
| You, H | 1 |
| Petrera, M | 1 |
| Paleari, L | 1 |
| Clavarezza, M | 1 |
| Puntoni, M | 1 |
| Caviglia, S | 1 |
| Briata, IM | 1 |
| Oppezzi, M | 1 |
| Mislej, EM | 1 |
| Stabuc, B | 1 |
| Gnant, M | 1 |
| Bachleitner-Hofmann, T | 1 |
| Roth, W | 1 |
| Scherer, D | 1 |
| Haefeli, WE | 1 |
| Ulrich, CM | 1 |
| DeCensi, A | 1 |
| Nguyen, TT | 1 |
| Ung, TT | 1 |
| Li, S | 2 |
| Lian, S | 1 |
| Xia, Y | 1 |
| Park, SY | 1 |
| Do Jung, Y | 1 |
| Amable, G | 1 |
| Martínez-León, E | 1 |
| Picco, ME | 1 |
| Di Siervi, N | 1 |
| Davio, C | 1 |
| Rozengurt, E | 1 |
| Rey, O | 1 |
| Au Yeung, SL | 1 |
| Luo, S | 1 |
| Schooling, CM | 1 |
| Cheng, Y | 1 |
| Shen, L | 1 |
| Tu, F | 1 |
| Xu, J | 1 |
| Liu, C | 1 |
| Cruz-Gil, S | 1 |
| Sánchez-Martínez, R | 1 |
| Wagner-Reguero, S | 1 |
| Stange, D | 1 |
| Schölch, S | 1 |
| Pape, K | 1 |
| Ramírez de Molina, A | 1 |
| Komiya, M | 1 |
| Fujii, G | 1 |
| Takahashi, M | 1 |
| Iigo, M | 1 |
| Mutoh, M | 1 |
| Spillane, S | 2 |
| Bennett, K | 2 |
| Sharp, L | 2 |
| Barron, TI | 2 |
| Adams-Campbell, LL | 1 |
| Chlebowski, RT | 1 |
| Gunter, MJ | 1 |
| Johnson, K | 1 |
| McTiernan, A | 1 |
| Simon, MS | 1 |
| Rohan, T | 1 |
| Wallace, RB | 1 |
| Smiechowski, B | 1 |
| Azoulay, L | 1 |
| Suissa, S | 1 |
| Zannella, VE | 1 |
| Dal Pra, A | 1 |
| Muaddi, H | 1 |
| McKee, TD | 1 |
| Stapleton, S | 1 |
| Sykes, J | 1 |
| Glicksman, R | 1 |
| Chaib, S | 1 |
| Zamiara, P | 1 |
| Milosevic, M | 1 |
| Wouters, BG | 1 |
| Bristow, RG | 1 |
| Koritzinsky, M | 1 |
| Takahashi, H | 5 |
| Hosono, K | 5 |
| Endo, H | 4 |
| Zhang, Y | 1 |
| Guan, M | 1 |
| Zheng, Z | 1 |
| Zhang, Q | 1 |
| Gao, F | 1 |
| Xue, Y | 1 |
| Zhang, ZJ | 3 |
| Mei, ZB | 1 |
| Liu, CY | 1 |
| Cui, A | 1 |
| Liang, ZL | 1 |
| Wang, GH | 1 |
| Cui, L | 1 |
| Wang, XW | 1 |
| Zhang, YJ | 1 |
| Sui, X | 1 |
| Xu, Y | 1 |
| Fang, Y | 1 |
| Lou, H | 1 |
| Han, W | 1 |
| Zhang, M | 1 |
| Chen, W | 1 |
| Wang, K | 1 |
| Li, D | 1 |
| Jin, W | 1 |
| Lou, F | 1 |
| Zheng, Y | 1 |
| Hu, H | 1 |
| Gong, L | 1 |
| Zhou, X | 1 |
| Pan, Q | 1 |
| Pan, H | 1 |
| He, C | 1 |
| Cardel, M | 1 |
| Jensen, SM | 1 |
| Pottegård, A | 1 |
| Jørgensen, TL | 1 |
| Hallas, J | 1 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Wang, QL | 1 |
| Liu, X | 2 |
| Dong, SH | 1 |
| Li, HX | 1 |
| Li, CY | 1 |
| Guo, LS | 1 |
| Gao, JM | 1 |
| Berger, NA | 1 |
| Li, L | 1 |
| Wu, YJ | 1 |
| Sehdev, A | 2 |
| Shih, YC | 1 |
| Vekhter, B | 1 |
| Bissonnette, MB | 1 |
| Olopade, OI | 1 |
| Polite, BN | 1 |
| Principi, M | 1 |
| De Censi, A | 1 |
| Łukasiewicz, D | 1 |
| Chodorowska, M | 1 |
| Jakubowska, I | 1 |
| Tsai, CC | 1 |
| Chuang, TW | 1 |
| Chen, LJ | 1 |
| Niu, HS | 1 |
| Chung, KM | 1 |
| Cheng, JT | 1 |
| Lin, KC | 1 |
| Gravitz, L | 1 |
| Lin, CM | 1 |
| Huang, HL | 1 |
| Chu, FY | 1 |
| Fan, HC | 1 |
| Chen, HA | 1 |
| Chu, DM | 1 |
| Wu, LW | 1 |
| Wang, CC | 1 |
| Chen, WL | 1 |
| Lin, SH | 1 |
| Ho, SY | 1 |
| Fransgård, T | 1 |
| Kowall, B | 1 |
| Stang, A | 1 |
| Rathmann, W | 1 |
| Kostev, K | 1 |
| Zanders, MM | 1 |
| van Herk-Sukel, MP | 1 |
| Vissers, PA | 1 |
| Herings, RM | 1 |
| Haak, HR | 1 |
| van de Poll-Franse, LV | 1 |
| O'Neil, BH | 1 |
| Mc Menamin, ÚC | 1 |
| Murray, LJ | 1 |
| Hughes, CM | 1 |
| Cardwell, CR | 1 |
| Jia, Y | 1 |
| Ma, Z | 1 |
| Zhou, W | 1 |
| Xu, X | 1 |
| Ren, G | 1 |
| Xu, G | 1 |
| Marks, AR | 1 |
| Pietrofesa, RA | 1 |
| Jensen, CD | 1 |
| Zebrowski, A | 1 |
| Corley, DA | 1 |
| Doubeni, CA | 1 |
| Jeong, YK | 1 |
| Kim, MS | 1 |
| Lee, JY | 1 |
| Kim, EH | 1 |
| Ha, H | 1 |
| He, XK | 1 |
| Su, TT | 1 |
| Si, JM | 1 |
| Sun, LM | 1 |
| Galal, MA | 1 |
| Ain-Shoka, AA | 1 |
| Komiya, Y | 1 |
| Umezawa, S | 1 |
| Sakai, E | 3 |
| Uchiyama, T | 4 |
| Taniguchi, L | 1 |
| Hata, Y | 2 |
| Uchiyama, S | 2 |
| Hattori, A | 1 |
| Nagase, H | 2 |
| Kessoku, T | 2 |
| Matsuhashi, N | 2 |
| Inayama, Y | 2 |
| Yamanaka, S | 2 |
| Taguri, M | 1 |
| Ridler, C | 1 |
| Nie, Z | 1 |
| Zhu, H | 1 |
| Gu, M | 1 |
| Jain, D | 1 |
| Chhoda, A | 1 |
| Uribe, J | 1 |
| Miranda, VC | 1 |
| Braghiroli, MI | 1 |
| Faria, LD | 1 |
| Bariani, G | 1 |
| Alex, A | 1 |
| Bezerra Neto, JE | 1 |
| Capareli, FC | 1 |
| Sabbaga, J | 1 |
| Lobo Dos Santos, JF | 1 |
| Hoff, PM | 1 |
| Riechelmann, RP | 1 |
| Park, SH | 1 |
| Kim, JL | 1 |
| Na, YJ | 1 |
| Jo, MJ | 1 |
| Jeong, YA | 1 |
| Lee, SY | 1 |
| Lee, SI | 1 |
| Lee, YY | 1 |
| Bordini, HP | 1 |
| Kremer, JL | 1 |
| Fagundes, TR | 1 |
| Melo, GP | 1 |
| Conchon-Costa, I | 1 |
| da Silva, SS | 1 |
| Cecchini, AL | 1 |
| Panis, C | 1 |
| Luiz, RC | 1 |
| Fernández-Fernández, FJ | 1 |
| Lan, B | 1 |
| Lu, D | 1 |
| Dai, Q | 1 |
| Hou, YC | 1 |
| Hu, Q | 1 |
| Huang, J | 1 |
| Fang, JY | 1 |
| Thent, ZC | 1 |
| Zaidun, NH | 1 |
| Azmi, MF | 1 |
| Senin, MI | 1 |
| Haslan, H | 1 |
| Salehuddin, R | 1 |
| Yan, L | 1 |
| Chu, Y | 1 |
| Rui, D | 1 |
| Nie, S | 1 |
| Xiang, H | 1 |
| Du, L | 1 |
| Wang, M | 1 |
| Kang, Y | 1 |
| Guo, M | 1 |
| Cheng, Z | 1 |
| Bi, C | 1 |
| Yang, B | 1 |
| Huang, CZ | 1 |
| Zhou, SN | 1 |
| Liu, Q | 1 |
| Liu, GJ | 1 |
| Chen, S | 1 |
| Han, FH | 1 |
| Han, MS | 1 |
| Meng, F | 1 |
| Wang, W | 1 |
| Nicolucci, A | 1 |
| Sugiyama, M | 2 |
| Suzuki, K | 2 |
| Nozaki, Y | 1 |
| Yoneda, K | 2 |
| Fujita, K | 1 |
| Yoneda, M | 1 |
| Inamori, M | 2 |
| Tomatsu, A | 1 |
| Chihara, T | 1 |
| Shimpo, K | 1 |
| Nakagama, H | 2 |
| Iida, H | 1 |
| Sakamoto, Y | 1 |
| Koide, T | 1 |
| Tokoro, C | 1 |
| Abe, Y | 1 |
| Lee, MS | 1 |
| Hsu, CC | 1 |
| Wahlqvist, ML | 1 |
| Tsai, HN | 1 |
| Chang, YH | 1 |
| Huang, YC | 1 |
| Svacina, S | 1 |
| Jeon, SM | 2 |
| Zheng, ZJ | 1 |
| Kan, H | 1 |
| Song, Y | 1 |
| Cui, W | 1 |
| Zhao, G | 1 |
| Kip, KE | 1 |
| Ioannou, GN | 1 |
| Boyko, EJ | 1 |
| Boghossian, S | 1 |
| Hawash, A | 1 |
| Bodmer, M | 1 |
| Becker, C | 1 |
| Meier, C | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Hassabo, HM | 1 |
| Bhadkamkar, NA | 1 |
| Wen, S | 1 |
| Baladandayuthapani, V | 1 |
| Kee, BK | 1 |
| Eng, C | 1 |
| Yamada, E | 1 |
| Fujisawa, N | 1 |
| Ezuka, A | 1 |
| Morita, S | 1 |
| Brower, V | 1 |
| Qiu, H | 1 |
| Rhoads, GG | 1 |
| Berlin, JA | 1 |
| Marcella, SW | 1 |
| Demissie, K | 1 |
| Haq, S | 1 |
| Ali, S | 1 |
| Mohammad, R | 1 |
| Sarkar, FH | 1 |
| Lee, DJ | 1 |
| Kim, B | 1 |
| Jung, JT | 1 |
| Lewis, JD | 1 |
| Capra, AM | 1 |
| Achacoso, NS | 1 |
| Levin, TR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. The ASAMET Trial[NCT03047837] | Phase 2 | 160 participants (Anticipated) | Interventional | 2017-03-15 | Recruiting | ||
| Endometrial Cancer Recurrence in Patients Taking Metformin[NCT05192850] | 100 participants (Anticipated) | Observational | 2021-12-27 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
37 reviews available for metformin and Colorectal Cancer
| Article | Year |
|---|---|
Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Odds Ratio; | 2022 |
A new contribution for an old drug: Prospect of metformin in colorectal oncotherapy.
Topics: Antineoplastic Agents; Colonic Neoplasms; Colorectal Neoplasms; Humans; Hypoglycemic Agents; Metform | 2021 |
Metformin: A Salutary Candidate for Colorectal Cancer Treatment in Patients with Diabetes.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; | 2019 |
Suppressive effects of metformin on colorectal adenoma incidence and malignant progression.
Topics: Adenoma; Asian People; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Disease Progression; Humans; | 2020 |
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Clinical Trials as Topic; Colorec | 2019 |
Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences.
Topics: Aged; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Male; Metform | 2020 |
Metformin, Microbiome and Protection Against Colorectal Cancer.
Topics: Animals; Anticarcinogenic Agents; Bacteria; Butyrates; Cell Transformation, Neoplastic; Colon; Color | 2021 |
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression.
Topics: Adenoma; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2020 |
Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Europe; Humans; Hypoglycemic Agents; Metformin | 2020 |
Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Cell Proliferation; Cell Transforma | 2021 |
How far along are we in revealing the connection between metformin and colorectal cancer?
Topics: Colonic Neoplasms; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Met | 2021 |
Repurposing metformin for the treatment of gastrointestinal cancer.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin | 2021 |
Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis.
Topics: Adenoma; Colorectal Neoplasms; Databases, Bibliographic; Diabetes Complications; Diabetes Mellitus; | 2017 |
[Effect of metformin on colorectal carcinoma in type 2 diabetes mellitus patients: a Markov model analysis].
Topics: Adult; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pros | 2017 |
Metformin and Colorectal Cancer - A Systematic Review.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin | 2019 |
For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis.
Topics: Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2020 |
Prevention and intervention trials for colorectal cancer.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; An | 2013 |
Colon epithelial proliferation and carcinogenesis in diet-induced obesity.
Topics: Aberrant Crypt Foci; Adiponectin; AMP-Activated Protein Kinases; Animals; Cell Proliferation; Cell T | 2013 |
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Diabetes Complications; Endometrial N | 2014 |
Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasm Staging; Proportional H | 2014 |
Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer.
Topics: Adenylate Kinase; Animals; Anticarcinogenic Agents; Bone Morphogenetic Proteins; Cell Differentiatio | 2014 |
Targeting mTOR network in colorectal cancer therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Autophagy; Colorectal Neopl | 2014 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
[Metformin can reduce the risk of colorectal cancer].
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Risk Factor | 2015 |
The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Diet; Exerc | 2015 |
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2016 |
Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; | 2016 |
Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis.
Topics: Adenoma; Aged; Chi-Square Distribution; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Hum | 2017 |
Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Colorectal | 2017 |
Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis.
Topics: Adenoma; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Metformin | 2017 |
Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies.
Topics: Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metfor | 2017 |
Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prognosis; | 2017 |
Epidemiological aspects of neoplasms in diabetes.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis | 2010 |
[Colorectal cancer and diabetes].
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Ri | 2011 |
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2011 |
Chemoprevention in colorectal cancer--where we stand and what we have learned from twenty year's experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anticarcinogenic Agents; Colorectal | 2012 |
The complexities of epidemiology and prevention of gastrointestinal cancers.
Topics: Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diabetes Complications; Folic Acid; Gastrointesti | 2012 |
11 trials available for metformin and Colorectal Cancer
| Article | Year |
|---|---|
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.
Topics: Colorectal Neoplasms; Female; Humans; Male; Metformin; Microsatellite Repeats; Middle Aged; Nivoluma | 2023 |
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.
Topics: Biomarkers; Breast Neoplasms; C-Reactive Protein; Colorectal Neoplasms; Combined Modality Therapy; E | 2020 |
The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
Topics: Aberrant Crypt Foci; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double- | 2020 |
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up | 2021 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bi | 2018 |
The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study.
Topics: Biomarkers; Breast Neoplasms; Cholesterol, HDL; Cholesterol, LDL; Colorectal Neoplasms; Coronary Art | 2019 |
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonic Polyps; Colonoscopy; Colorectal Ne | 2016 |
Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2016 |
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Topics: Aberrant Crypt Foci; Adenoma; Aged; Antineoplastic Agents; Cell Proliferation; Clinical Trials as To | 2010 |
Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Colonic Polyps; Colorectal Neoplasms; Doubl | 2012 |
117 other studies available for metformin and Colorectal Cancer
| Article | Year |
|---|---|
Metformin-loaded lecithin nanoparticles induce colorectal cancer cytotoxicity via epigenetic modulation of noncoding RNAs.
Topics: Antineoplastic Agents; Cadherins; Cell Death; Cell Line, Tumor; Chitinase-3-Like Protein 1; Colorect | 2021 |
The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer.
Topics: Adenoma; Colorectal Neoplasms; Fluorouracil; Humans; Hypoglycemic Agents; Incidence; Metformin | 2022 |
Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas.
Topics: Adenoma; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Humans; Metfo | 2022 |
A functional screen with metformin identifies microRNAs that regulate metabolism in colorectal cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, | 2022 |
Chemoprevention for Colorectal Cancers: Are Chemopreventive Effects Different Between Left and Right Sided Colorectal Cancers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Cyclooxygen | 2022 |
Metformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-β/PI3K/AKT signaling transduction.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; | 2022 |
FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Ferroptosis; | 2022 |
Metformin-induced reductions in tumor growth involves modulation of the gut microbiome.
Topics: Animals; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Microbiom | 2022 |
Effects of diabetes type 2 and metformin treatment in Swedish patients with colorectal cancer.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sweden | 2022 |
Cytotoxic effect of metformin on butyrate-resistant PMF-K014 colorectal cancer spheroid cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Butyrates; Cell Line, Tumor; Colorectal Neopla | 2022 |
Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple kinase pathways.
Topics: AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Humans; M | 2023 |
Metformin inhibits the development and metastasis of colorectal cancer.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Cell Line, Tumor; Colorectal Neoplasms; Huma | 2022 |
Metformin use is not associated with colorectal cancer incidence in type-2 diabetes patients: evidence from methods that avoid immortal time bias.
Topics: Bias; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metfo | 2022 |
The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Retrospecti | 2022 |
Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men.
Topics: Aged; Breast Neoplasms, Male; Colorectal Neoplasms; Humans; Male; Medicare; Metformin; Prostate; Pro | 2022 |
Metformin reprograms tumor microenvironment and boosts chemoimmunotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Humans; Hyaluronic Acid; Immunotherap | 2022 |
Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Humans; Immune Checkpoint Inhibitors; Immunologic F | 2022 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Phosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Metformin; Signal Tr | 2023 |
Elevated basal AMP-activated protein kinase activity sensitizes colorectal cancer cells to growth inhibition by metformin.
Topics: AMP-Activated Protein Kinases; Colorectal Neoplasms; Humans; Metformin; Phosphorylation; Signal Tran | 2023 |
The impact of metformin on survival in diabetes patients with operable colorectal cancer: A nationwide retrospective cohort study.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Neoplasms; Metfo | 2023 |
Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer.
Topics: CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Humans; Immunosuppression Therapy; Metformin; Tryp | 2023 |
Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer.
Topics: Adenocarcinoma; Colorectal Neoplasms; Female; Humans; Intra-Abdominal Fat; Male; Metformin; Obesity, | 2023 |
Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening.
Topics: Adenoma; Biological Specimen Banks; Colorectal Neoplasms; Drug Evaluation, Preclinical; Humans; Metf | 2023 |
[Metformin inhibits self-renewal of colorectal cancer stem cells by inhibiting mitochondrial oxidative phosphorylation].
Topics: Antibodies; Colorectal Neoplasms; Galactose; Humans; Metformin; Oxidative Phosphorylation; Reactive | 2023 |
Nuclear VCP drives colorectal cancer progression by promoting fatty acid oxidation.
Topics: Carnitine O-Palmitoyltransferase; Colorectal Neoplasms; Fatty Acids; Humans; Metformin; Neoplastic P | 2023 |
The Use of Metformin and Postoperative Insulin Pump Were Predictive Factors for Outcomes of Diabetic Colorectal Cancer Patients after Surgery.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Insulins; Metformin; Postoperative Complica | 2023 |
Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: national cohort study.
Topics: Aged; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycem | 2020 |
Insulin enhances and metformin reduces risk of colorectal carcinoma in type-2 diabetes.
Topics: Adult; Aged; Colorectal Neoplasms; Comorbidity; Databases, Factual; Diabetes Mellitus, Type 2; Femal | 2020 |
Metformin in colorectal cancer: A match ruled by MiR26b?
Topics: Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Humans; Metformin | 2020 |
Response to Letter to the Editor: Metformin in colorectal cancer: A match ruled by MiR26b?
Topics: Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Humans; Metformin | 2020 |
Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes.
Topics: Aged; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Early Detection of Cancer; Female; Follow-Up | 2019 |
Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study.
Topics: Aged; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Male; Metform | 2020 |
Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Colorectal | 2020 |
Metformin selectively inhibits metastatic colorectal cancer with the
Topics: Animals; Colorectal Neoplasms; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferase 1; Female; | 2020 |
Use of metformin and risk of breast and colorectal cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Colorectal Neoplasms; Diabetes Mell | 2020 |
Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy.
Topics: Animals; Apoptosis; Autophagy; Colorectal Neoplasms; Metformin; Mice; Mutation; Tumor Suppressor Pro | 2020 |
Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 2020 |
Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colo | 2020 |
Metformin usage and the risk of colorectal cancer: a national cohort study.
Topics: Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; | 2021 |
Negative Regulation of ULK1 by microRNA-106a in Autophagy Induced by a Triple Drug Combination in Colorectal Cancer Cells
Topics: Autophagy; Autophagy-Related Protein-1 Homolog; Autophagy-Related Proteins; Beclin-1; Cell Prolifera | 2021 |
Metformin and colonic polyps in acromegaly: is the solution closer than we think?
Topics: Acromegaly; Colonic Polyps; Colorectal Neoplasms; Diabetes Mellitus; Human Growth Hormone; Humans; I | 2021 |
Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; Data Analysis; Diab | 2021 |
Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.
Topics: Animals; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemother | 2021 |
Metformin Inhibits the Urea Cycle and Reduces Putrescine Generation in Colorectal Cancer Cell Lines.
Topics: Animals; Biomarkers; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neopla | 2021 |
Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Culture Media; Glucose; Humans; Hypoglyc | 2021 |
Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis.
Topics: Aged; Colorectal Neoplasms; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce | 2017 |
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Letter.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; United States; Vet | 2017 |
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Response.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; United States; Vet | 2017 |
Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Calcitriol; Cell Respiration; Cell Survival; C | 2017 |
Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Diabetes Mellitus, Type | 2017 |
Comment on: Need for Differentiating Diabetes-Specific Mortality from Total Mortality when Comparing Metformin with Insulin Regarding Cancer Survival.
Topics: Colorectal Neoplasms; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Metformin | 2017 |
Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Colo | 2017 |
The key genes underlying pathophysiology association between the type 2-diabetic and colorectal cancer.
Topics: Colorectal Neoplasms; Computational Biology; Diabetes Mellitus, Type 2; Gene Expression Regulation, | 2018 |
Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism.
Topics: Adenylate Kinase; Animals; Benzophenanthridines; Cell Line, Tumor; Colorectal Neoplasms; Drug Resist | 2018 |
14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma.
Topics: 14-3-3 Proteins; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Color | 2018 |
Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Disease-Free Surviv | 2018 |
Studying the Effects of Nonindicated Medications on Cancer: Etiologic versus Action-Focused Analysis of Epidemiologic Data.
Topics: Bias; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2018 |
A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus.
Topics: Adult; Aged; Bias; California; Colorectal Neoplasms; Data Interpretation, Statistical; Diabetes Mell | 2018 |
Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Gene Expression Regulation, Neoplastic; HMG | 2018 |
The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC).
Topics: Cell Movement; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; HCT116 C | 2018 |
Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 2018 |
Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apopt | 2018 |
Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling.
Topics: Colorectal Neoplasms; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; HCT116 Cells | 2018 |
Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Epithelial | 2018 |
Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells
Topics: Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Methylati | 2018 |
Metformin and Colorectal Cancer Risk-Letter.
Topics: Cohort Studies; Colorectal Neoplasms; Humans; Hypoglycemic Agents; Metformin; Risk | 2018 |
Molecular mechanism of LKB1 in the invasion and metastasis of colorectal cancer.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Prolifer | 2019 |
Metformin attenuates cells stemness and epithelial‑mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β‑catenin pathway.
Topics: beta Catenin; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Epithelial-Mesenchymal Tran | 2019 |
Metformin inhibits lithocholic acid-induced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity.
Topics: Colorectal Neoplasms; HCT116 Cells; Humans; Interleukin-8; Lithocholic Acid; Metformin; NF-kappa B; | 2019 |
Metformin inhibits β-catenin phosphorylation on Ser-552 through an AMPK/PI3K/Akt pathway in colorectal cancer cells.
Topics: AMP-Activated Protein Kinases; beta Catenin; Cell Line; Colorectal Neoplasms; Humans; Metformin; Pho | 2019 |
A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment.
Topics: Animals; Antineoplastic Agents; Coenzyme A Ligases; Colorectal Neoplasms; Down-Regulation; Fluoroura | 2019 |
A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer.
Topics: Aged; Aged, 80 and over; Cohort Studies; Colorectal Neoplasms; Female; Humans; Hypoglycemic Agents; | 2013 |
Diabetes, metformin use, and colorectal cancer survival in postmenopausal women.
Topics: Aged; Aged, 80 and over; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus; Female; Humans; Hy | 2013 |
The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus.
Topics: Aged; Case-Control Studies; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; | 2013 |
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response.
Topics: Animals; Cell Hypoxia; Colorectal Neoplasms; Electron Transport Complex I; HCT116 Cells; Humans; Mal | 2013 |
Effects of metformin on CD133+ colorectal cancer cells in diabetic patients.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Apoptosis; beta | 2013 |
Metformin exposure and disseminated disease in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Databases, Factual; Dose-Response Relationship, Drug; | 2014 |
Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis | 2014 |
Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Fema | 2014 |
Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice.
Topics: Aberrant Crypt Foci; Animals; Anticarcinogenic Agents; Blotting, Western; Cholecalciferol; Colorecta | 2015 |
Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population.
Topics: Adult; Case-Control Studies; Colorectal Neoplasms; Databases, Factual; Diabetes Mellitus; Female; Fo | 2015 |
Prevention of colorectal adenomas.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Lig | 2015 |
[Obesity as a factor in the development of cancer in type 2 diabetes].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans | 2015 |
Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; | 2015 |
Prevention: Tending the gut.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cancer Vaccines; Clinical Trials as Topic; Colonic | 2015 |
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study.
Topics: Adult; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus; Female; Glycoside Hydrolase Inhibito | 2015 |
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colorectal Neoplasms; Databases, Factual; Diabetes | 2015 |
Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
Topics: Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus; F | 2015 |
Metformin use and survival after colorectal cancer: A population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Fem | 2016 |
Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Colorect | 2015 |
Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Colon; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Fem | 2015 |
Increased 30-day mortality in patients with diabetes undergoing surgery for colorectal cancer.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Comorbidity; Denmark; Diabetes Mellitus; Female; Huma | 2016 |
Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins.
Topics: Animals; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Damag | 2015 |
Metformin Increases Overall Survival in Patients with Diabetes Undergoing Surgery for Colorectal Cancer.
Topics: Aged; Colorectal Neoplasms; Combined Modality Therapy; Denmark; Diabetes Mellitus; Female; Follow-Up | 2016 |
Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Caco-2 Cells; Cell Proliferation; Colorectal Neo | 2016 |
Therapy: Metformin protective against colorectal cancer?
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2016 |
Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and Advanced Adenoma Among DM II.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabetes Complication | 2016 |
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; K | 2016 |
Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Humans; Metformin; Myel | 2016 |
Protective effect of metformin in an aberrant crypt foci model induced by 1,2-dimethylhydrazine: Modulation of oxidative stress and inflammatory process.
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; AMP-Activated Protein Kinases; Animals; Cell Proliferati | 2017 |
Antineoplastic potential of metformin in colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Humans; Hypoglycemic Agents; Metformin | 2017 |
Metformin suppresses CRC growth by inducing apoptosis via ADORA1.
Topics: Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; | 2017 |
Metformin depresses overactivated Notch1/Hes1 signaling in colorectal cancer patients with type 2 diabetes mellitus.
Topics: Cell Differentiation; Cell Proliferation; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; H | 2017 |
The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma.
Topics: Adenoma; Colorectal Neoplasms; Diabetes Mellitus; Female; Humans; Male; Metformin; Neoplasm Recurren | 2017 |
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Apoptosis; Azoxymethane; Cell Proli | 2010 |
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.
Topics: Adult; Aged; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I | 2011 |
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus; Fem | 2012 |
Metformin and colorectal cancer risk in diabetic patients.
Topics: Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2011 |
Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis.
Topics: Aged; Case-Control Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypogly | 2012 |
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypogl | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Colonoscopy; Colorectal Neoplasms; Diab | 2012 |
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; | 2013 |
[The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Diabetes Mellitus; Dise | 2012 |
[What Is the effect of metformin combined to chemotherapy in stage IV colorectal cancer with diabetes?].
Topics: Colorectal Neoplasms; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metformin | 2012 |
Medical therapy for diabetes is associated with increased use of lower endoscopy.
Topics: Aged; Bias; Cohort Studies; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Diabetes Mellitus, Ty | 2007 |